A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

541

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: DB-1303/BNT323
DRUG: Capecitabine
DRUG: Paclitaxel
DRUG: Nab-paclitaxel

Sponsor

DualityBio Inc.

Collaborators

[object Object]